Autolus Therapeutics Ltd (AUTL NASDAQ) stock market data APIs
$2.4231
0.01(0.4%)
as of July 18, 2025
Try our APIs with
free plan!
Autolus Therapeutics Ltd Financial Data Overview
Price chart is built with
Anychart
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Prev. Close
2.4231
Open
2.4356
High
2.5087
Low
2.4006
52 wk Range
1.105-5
Market Cap
649 M
Shares Outstanding
266 M
Revenue
9 011 K
EPS
-0.26
Beta
1.739
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Autolus Therapeutics Ltd data using free add-ons & libraries
Get Autolus Therapeutics Ltd Fundamental Data
Autolus Therapeutics Ltd Fundamental data includes:
- Net Revenue: 9 011 K
- EBITDA: -259 082 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: -0.26
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Autolus Therapeutics Ltd News
New
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering n...
Needham Reiterates a Buy Rating on Autolus Therapeutics (AUTL), Keeps the PT at $10
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Analyst Gil Blum from Needham reiterated a Buy rating on Autolus Therapeutics plc (NAS...
Ardelyx Leads The Pack Of 3 Promising Penny Stocks
The market has been flat over the last week but is up 11% over the past year, with earnings forecast to grow by 15% annually. For investors willing to explore beyond established giants, penny stocks�...
SA Asks: Which oncology companies are attractive M&A targets?
[word m and a made with wood building blocks, stock image] Maksim Labkouski Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor [https://see...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
